Equities

Aroa Biosurgery Ltd

Aroa Biosurgery Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.65
  • Today's Change-0.005 / -0.76%
  • Shares traded382.68k
  • 1 Year change-27.78%
  • Beta1.1719
Data delayed at least 20 minutes, as of Jul 05 2024 07:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aroa Biosurgery Limited is a soft-tissue regeneration company. It develops, manufactures, sells, distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from the AROA extracellular matrix (ECM) technology platform, an extracellular matrix biomaterial derived from ovine forestomach. AROA ECM is an ECM biomaterial containing a rich and complex mix of biological molecules that is the building block for a range of soft tissue repair products. Its products include Endoform, Myriad Matrix, Myriad Morcells, Myriad Morcells Fine, Symphony and Reinforced Bioscaffolds. Endoform products support all phases of wound healing and are appropriate for use early in wound management to restore protease balance and advance healing to the proliferative phase. Myriad Matrix is an engineered ECM for soft tissue repair, reinforcement, and complex wounds.

  • Revenue in AUD (TTM)62.86m
  • Net income in AUD-9.67m
  • Incorporated2007
  • Employees261.00
  • Location
    Aroa Biosurgery Ltd64 Richard Pearse Drive, MangereAUCKLAND 2022New ZealandNZL
  • Phone+64 98693035
  • Websitehttps://aroa.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Imricor Medical Systems Inc918.21k-33.75m114.62m--------124.83-0.2144-0.21440.0059-0.07730.05590.87492.38---205.60-93.47-294.49-106.30-181.27-134.71-3,675.60-2,462.890.4944-3.6415.92---24.56-9.29-30.36---10.82--
ImpediMed Ltd10.47m-19.42m141.62m76.00--2.78--13.52-0.0102-0.01020.00550.02520.19611.324.41137,802.60-36.37-52.27-40.94-62.3486.9580.64-185.47-264.766.85--0.0244--7.3627.87-3.26--37.83--
Mach7 Technologies Ltd26.97m-5.55m153.19m90.00--2.8170.785.68-0.0231-0.02310.11230.22560.3605--3.21---7.42-7.48-8.73-8.6595.0993.72-20.59-20.56---2,605.170.0193--10.9728.3074.85--29.28--
EMvision Medical Devices Ltd8.86m-3.22m170.42m----27.24--19.23-0.0449-0.04490.11860.07330.7954-------28.95-67.20-45.25-79.38-----36.40-175.99---35.200.3424--62.0870.4736.64------
Genetic Signatures Ltd16.49m-18.04m179.31m----3.34--10.87-0.1245-0.12450.11360.21720.33661.065.25---36.81-7.14-40.19-7.8240.6657.68-109.38-13.745.95-18,040.000.0003---38.1133.44-558.77--73.20--
Cyclopharm Limited32.21m-4.70m184.49m87.00--4.84--5.73-0.0508-0.05080.34760.34280.67481.114.13370,173.10-9.85-12.60-11.92-14.9468.1570.20-14.60-25.472.32-18.400.1159--11.2215.5028.90---7.83-12.94
Optiscan Imaging Ltd1.68m-5.44m213.01m8.00--12.99--126.79-0.0074-0.00740.00230.01960.1344-0.52531.48---43.54-47.55-50.01-57.08148.555.08-323.87-254.449.43--0.0269--65.86-5.23-2.80---15.27--
4DMedical Ltd1.03m-30.83m223.67m----2.34--218.16-0.0882-0.08820.00290.23320.00980.0920.1585---29.47-43.96-39.07-57.5895.0032.30-3,007.64-2,704.361.79--0.0476---31.84-1.86-27.92--2.46--
Aroa Biosurgery Ltd62.86m-9.67m225.46m261.00--2.61--3.59-0.0281-0.02810.18280.25110.6071.562.82---9.34-10.37-10.11-12.5285.3980.63-15.39-20.316.40--0.0726--9.0124.26-2,583.84--33.65--
Medadvisor Ltd109.43m-9.03m269.77m100.00--4.81--2.47-0.0166-0.01660.20060.1020.9056--4.68---7.47-24.51-13.47-36.7658.8959.77-8.25-26.98---3.040.1847--44.6067.6634.83---15.12--
EBR Systems Inc0.00-52.26m328.14m----7.06-----0.1804-0.18040.000.15090.00-------46.54---50.70-------------28.660.5609-------5.89------
Data as of Jul 05 2024. Currency figures normalised to Aroa Biosurgery Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

14.35%Per cent of shares held by top holders
HolderShares% Held
Harbour Asset Management Ltd.as of 30 Apr 202422.69m6.59%
Wilson Asset Management (International) Pty Ltd.as of 30 Jun 202316.06m4.67%
Guardians of New Zealand Superannuationas of 30 Jun 20235.39m1.57%
Norges Bank Investment Managementas of 31 Dec 20233.41m0.99%
DFA Australia Ltd.as of 31 May 20241.31m0.38%
Dimensional Fund Advisors LPas of 30 Apr 2024347.61k0.10%
FCA Corp.as of 30 Apr 2024145.00k0.04%
Dimensional Fund Advisors Ltd.as of 06 Jun 202452.94k0.02%
Acadian Asset Management LLCas of 31 Mar 20240.000.00%
More ▼
Data from 30 Jun 2023 - 20 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.